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Malignantmelanomarepresents thethirdmostcommoncauseforcerebralmetastasesafterbreastandlungcancer.Centralnervous
system (CNS) metastases occur in 10 to 40% of patients with melanoma. Most of the symptoms of CNS melanomametastases are
unspeciﬁc and depend on localization of the lesion. All patients with new neurological signs and a previous primary melanoma
lesion must be investigated. Although primary diagnosis may rely on computed tomography scan, magnetic resonance images
are usually used in order to study more precisely the characteristics of the lesions in and to embase the surgical plan. Other
possible complementary exams are: positron emission tomography, iofetamine cintilography, immunohistochemistry of liquor,
monoclonal antibody immunocytology, optical coherence tomography, and transcriptase-polymerase chain reaction. Treatment
procedures are indicated based on patient clinical status, presence of unique or multiple lesions, and family agreement. Often
surgery,radiosurgery,wholebrainradiotherapy,andchemotherapyarecombinedinordertoobtainlongerremissionsandoptimal
symptomrelieve. Corticoidsmaybe alsousefulinthosecasesthatpresent withremarkableperitumoraledemaandimportantmass
eﬀect. Despite of the advance in therapeutic options, prognosis for patients with melanoma brain metastases remains poor with a
median survival time of six months after diagnosis.
1.Introduction
Metastatic spread of tumor cells detached from melanoma
into the central nervous system (CNS) occurs haematogeni-
cally since lymphatic drainage is absent in the brain [1]. The
blood-brain barrier is usually intact in metastases that are
smaller than 0.25mm in diameter [2].
The cells from brain metastases show a slower growth
rate and exhibit lower metastatic potential than cells from
visceral metastases, indicating that brain metastases do
not necessarily represent the end stage in the metastatical
cascade. Rather, brain metastases are likely to originate from
auniquesubpopulationofcellswithintheprimary neoplasm
[2].
2.Classiﬁcation
Some authors found an association between the size of
the cerebral metastatic lesion from malignant melanoma
and clinical parameters characteristic of tumor behavior.
They classiﬁed the metastases from melanomas to their size:
smaller than 1cm (group A), between 1 and 4cm (group B),
and biggerthan 4cm (groupC),inorder toassess theclinical
course of the disease and predict the response to treatment.
Group B lesions are the most common, independent of
the site of the primary tumor, except for patients with
rectal melanoma. Group C metastases are the least common
and are usually solitary. Asymptomatic patients usually
have group A metastases, whereas those with nonspeciﬁc
complaints or behavioural changes usually have group B
metastases. Solitary lesions usually belong to groups B or C,
whereas multiple lesions belong mainly to groups A or B [3].
3.Epidemiology
CNS metastases occur in 10 to 40% of melanoma patients in
clinical studies and up to 90% in autopsy studies [1]. In 15%
to 20% of these patients, the CNS is the ﬁrst site of relapse.2 ISRN Surgery
In 41% a second organ is involved, and in 20% three organs
are involved [4–7].
The cumulative risk at 5 years for patients with
melanoma to develop CNS metastases corresponds to about
7% [8]. Fifty-eight percent of the patients with intracranial
metastasis in malignant melanoma are male and 42% were
female [9]. Brain metastases account for 20–54% of reported
deaths from melanoma [8]. Malignant melanoma represents
the third most common cause for central nervous system
metastases after breast and lung cancer [10]. Whereas breast,
lung, and kidney metastases are predominantly solitaire,
malignant melanoma metastasizes often in a multiple way.
Nevertheless, only about 5% of the patients with multiple
melanoma metastases have more than ﬁve intracerebral
metastatical lesions.
Seventy-one percent of the primary lesions are invasive
lesions with mean greater than thickness of 3.5mm. Nev-
ertheless, the studies have showed a signiﬁcative prevalence
of small and well-circumscribed lesions at surgical aspect.
There are also observed indolent lesions with a long time of
evolution[9].
The case of disseminated carcinomatous cell spreading
throughout the brain is called “military metastases” or
“carcinomatous encephalitis.” This condition is very rare
and correlated with a poor prognosis. Most patients with
advanced military metastases will have widespread extracra-
nial disease, but the majority will die from intracerebral
spread.
4.RiskFactors
Risk factors for central nervous system (CNS) metastases
among patients with coetaneous malignant melanoma are:
male, head and neck or oral primary lesion, presence of
visceral metastases, mainly lung, primary tumor thickness
and ulceration of primary lesion. Age and race are not
signiﬁcant factors [11, 12].
5.MolecularBiology
5.1. Endothelial Cell Heparanases. One of the many features
of the malignant melanoma phenotype, in vitro and in vivo,
is the elevated heparanase production and activity, which
confers the capacity of degrading the subendothelial matrix
produced by endothelial cell monolayer cultures. Supra-
additive levels of heparanase activity are found when brain
endothelial cells are coincubated with brain-metastatical
melanoma cells in equicellular amounts [13].
Murine and human brain-metastatical melanoma cells
solubilize sulfated matrix proteoglycansat levelssigniﬁcantly
higher than their parental lines. Sulfated matrix proteo-
glycans are rich in heparan sulfate (HSPGs), with minor
amounts of chondroitin and dermatan sulfates. The pattern
of HSPG degradation by brain-metastatical melanoma cells
diﬀers from that of less metastatical parental cells or cells
metastatical to organs other than the brain. Cooperative
interactions between heparanases from tumor and endothe-
lial sources are suggested to be a signiﬁcative mechanism in
the invasion process.
5.2. Neurotrophins. The brain is a uniquemicroenvironment
enclosed by the skull and maintaining a highly regulated
vascular transport barrier. To metastasize to the brain,
malignant tumorcellsmust attach to microvessel endothelial
cells, invade the blood-brain barrier (BBB), and respond to
brain survival and growth factors.
Neurotrophins (NTs) are important in brain invasion
because they stimulate this process. In brain-metastatic
melanoma cells, NTs can promote invasion by enhancing
the production of extracellular matrix degradative enzymes
such as heparanase, an enzyme capable of locally destroying
boththeextracellularmatrix and thebasement membrane of
the BBB. Melanoma cell lines exhibiting low ability to form
brain metastases express low-aﬃnity neurotrophin receptor
p75NTR in relation to their brain-metastatic potentials.
Presence of functional TrkC, the putative receptor for the
invasion-promoting neurotrophin NT-3, is also expressed in
brain-metastatic potential cells.
Brain-metastatic melanoma cells can also produce auto-
crine factors and inhibitors that inﬂuence their growth,
invasion, and survival in the brain. Synthesis of these factors
may inﬂuence NTs production by brain cells adjacent to
the neoplastic invasion front, such as oligodendrocytes and
astrocytes. In brain biopsies, increased amounts of nerve
growth factor (NGF) and NT-3 were observed in tumor-
adjacent tissues at the invasion front of human melanoma
tumors. Astrocytes are supposed to contribute to the brain-
metastatic speciﬁty of melanoma cells by producing NTs-
regulated heparanase. Trophic, autocrine, and paracrine
growth factors may, therefore, determine whether metastat-
ical cells can successfully invade, colonize, and grow in the
central nervous system [14].
5.3. Integrin alpha(v)beta(3). Integrin alpha(v)beta(3) is a
molecule of adhesion to the endothelium, and its expression
on the metastatical pattern of human melanoma cells
in the central nervous system (CNS) is already studied.
Although it is predicted that the adhesion of tumor cells
to endothelial cells plays a role in this phenomenon, tumor
cell alpha(v)beta(3) integrand expression per se does not
explain the diﬀerence in metastatic behavior in the CNS.
Probably others yet unknown factors must be involved
[15].
6. Signs andSymptoms
Headache is the most common presenting symptom, but
brain metastases should be suspected in all melanoma
patients with new neurological ﬁndings [1]. In patients with
brain metastasis, melanoma is one of the primaries cancers
with the highest frequency of seizures, found in about one
third of the patients [16]. Mean time interval between the
initial diagnosis of melanoma and development of ﬁrst
symptoms of CNS metastases is 3.5 years [9].
6.1. Diagnosis. Brain metastases are clinically diagnosed in
the majority of patients with metastatic melanoma. The
time from diagnosis of the primary tumor to discovery of
disease in the CNS is signiﬁcantly longer for those who hadISRN Surgery 3
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Figure 1: (a) axial T1-Weighted MRI after injection of Gadolinium, demonstrating an intraparietal lesion with heterogeneous appearance,
presenting hypersignal intercalted with necrotic areas. (b) The same lesion in a coronal view.
group A lesions (metastases smaller than 1cm), compared
with those who had groups B (metastases between 1 and
1.4cm) or C lesions (metastases bigger than 4cm) [17, 18].
Inpatients whose disease had progressed tobrain metastases,
freedomfromsuchmetastases decreaseslogarithmically with
time from initial presentation. This suggests a random
distribution of progression rates with a mean time of 2.5
years between diagnosis and development of intracranial
metastases [19].
6.1.1. Computed Tomographic (CT). All patient with new
neurological signs and a previous primary melanoma lesion
must be investigated. CT scan ﬁnds solitary lesions in 54.2%
and multiple lesions in 45.8% of patients with malignant
melanoma cerebral metastasis. Eighty-four percent of the
solitary lesions are located in the cerebral hemispheres with
62.5% of these in the frontal region.
Seventy-ﬁve percent of the CNS metastatic melanoma
lesions appear on noncontrast study as increased density;
22% are hypodense, and 3% are isodense. All lesions show
contrast enhancement, usually appearing as a homogeneous
nodular or ring pattern [20].
6.1.2. Magnetic Resonance Images (MRI). MRI is the best
diagnostic technique for detecting CNS metastases [1]
(Figure 1). However, large, solitary, necrotic metastases can
be indistinguishable from high-grade astrocytomas. Using
conventional MRI, the demonstration of an elevated rCBV
(relative cerebral blood volume CBV—the ratio between the
normal adjacent and the pathological area) may suggest a
hypervascular lesion such as renal carcinoma or melanoma
[21].
Most commonly, CNS melanoma metastasis appears in
MRI as hyperintense (Figure 2) on T1-weighted images and
hypointense on T2-weighted images. Hemorrhage in the
lesion may have a greater inﬂuence on this unique appear-
ance than does melanin. The increased tissue sensitivity of
MRI allow for 22% of patients greater lesion detection than
did CT [22].
Figure 2:CTdemonstratingmultiplemelanomametastaticlesions.
Observe the typical hyperintense signal and the corticosubcortical
localization. Note also the presence of an external derivation
catheter in left ventricle as an attempt to alleviate intracranial
hypertension.
6.1.3. Optical Coherence Tomography (OCT). Intraoperative
identiﬁcation of brain tumors and tumor margins has been
limited by either the resolution of the in vivo imaging tech-
nique or the time required to obtain histological specimens.
Optical coherence tomography (OCT) is a new, non-
contact, high-speed and high-resolution, real-time, intra-
operative imaging technique, capable of resolutions on
micrometer scale, which has been used to identify intra-
cortical melanomas. OCT is analogous to ultrasound B-
mode imaging, except that reﬂections of infrared light,
rather than sound, are detected. OCT uses inherent tissue
contrast, rather than enhancement with dyes, to diﬀerentiate
tissue types. The compact, ﬁber-optic-based design is readily
integrated with surgical instruments.
Two-dimensional images show increased optical back-
scatter from regions of metastatic melanoma tumors, which
are quantitatively used to determine the tumor margin.
The images correlate well with the histological ﬁndings.4 ISRN Surgery
Three-dimensional reconstructions reveal regions of tumor
penetrating normal cortex and can be re-cut at arbitrary
planes. Subsurface cerebral vascular structures can be identi-
ﬁed and are then avoided during the surgery. The Literature
reports suggest that OCT can eﬀectively diﬀerentiate normal
cortex from intracortical melanoma based on variations in
optical backscatter [23]. High-resolution and high-speed
imaging capabilities of OCT may permit the intraoperative
identiﬁcation of tumor and more precise localization of
tumor margins.
6.1.4. Positron Emission Tomography (PET). Detection and
diagnosis of human malignant melanoma by Positron Emis-
sion Tomography (PET) using 18F-10B-L-BPA, a speciﬁc
melanogenesis-seeking compound, has been developed.This
resulted in a novel, highly eﬀective methodology for the
selective three dimensional imaging of metastatic malignant
melanomas, and for accurate determination of 18F-10B con-
centration in the tumor and surrounding tissue, providing
almost all diagnostic information necessary for complete
noninvasive radiation dose planning in the treatment of
malignant melanoma [24].
6.1.5. Iofetamine (I 123) Cintilography. The Literature data
show that iofetamine (I 123) cintilography can be a good
method to diﬀerential diagnostic in patients with risk for
metastatic melanoma lesions. In patients with metastatic
melanoma lesions, cintilography shows increased uptake
of iofetamine (I 123). Studies suggest that certain brain
tumors such as melanoma are capable of selectively binding
iofetamine I 123 because of speciﬁc chemical properties of
this radiopharmaceutical compound. The sensibility of this
method is 80% and the speciﬁcity 97.8% [25].
6.1.6. Immunohistochemistry. Intermediate ﬁlament keratin
is regarded as a good marker for epithelial and mesothelial
tumors. In the intracranial and intraspinal spaces keratin
has been demonstrated only in the endocrine cells of the
adenohypophysis, squamous epithelial islands in the pars
tuberalis of the hypophysis, and in the choroid plexus
epithelium. Since gliomas and meningiomas do not express
keratin, immunohistochemistry essay for keratin provide
an additional help for diﬀerentiating between metastatic
melanomas and primary central nervous system tumors [8].
6.1.7. Monoclonal Antibody Immunocytology. The addition
of monoclonal antibody immunocytology to conventional
techniques signiﬁcantly improves the sensitivity of CSF
cytology. This is particularly useful in the diagnosis of
“Neoplastic meningitis,” also called metastatic meningeal
melanomatosis (MMM) a complication of malignant
melanoma disease whose diagnosis rests on the demonstra-
tion of malignant cells within the CSF [26].
The putative CSF tumor markers, ﬁbronectin, and
beta 2-microglobulin, are elevated signiﬁcantly in MMM
(metastatic meningeal melanomatosis) but not in patients
with solid cerebral metastases. A prominent increase in
the IgM index, which reﬂects intrathecal B-cell stimulation,
and rise of IgG index, interleukin-6, and tumor necrosis
factor-alpha in MMM patients provide preliminary evi-
dence for a local intrathecal immune response triggered by
melanoma cell invasion of the subarachnoid space [27].
6.1.8. Transcriptase-Polymerase Chain Reaction (RT-PCR).
Diagnosis of melanoma CNS metastases typically is made
following the onset of clinical symptoms. Thus, more sensi-
tive diagnostic approaches are needed to identify subclinical
CNS metastases. Currently, standard cytological analysis of
thecerebrospinalﬂuid(CSF)islimitedbyitspoorsensitivity.
A more sensitive assay was therefore developed using mul-
tiple reverse transcriptase-polymerase chain reaction (RT-
PCR) markers.
The CSF is collected and assessed by RT-PCR for three
known melanoma-associated markers (MAGE-3, MART-1,
and tyrosinase) to detect occult metastatic melanoma cells
in the CSF. The correlation between CSF RT-PCR positivity
of MART-1 and/or MAGE-3 and the development of CNS
metastases is signiﬁcant. Of the patients with positive CSF
RT-PCR markers, 41% have either positive MRI and/or
positive RT-PCR results [28].
6.2. Treatment. The optimal treatment of melanoma pa-
tients with CNS metastases depends on each situation.
Often surgery, radiosurgery, whole brain radiotherapy and
chemotherapy are used in combination to obtain longer
remissions and optimal symptom relieve [1]. Patients with
multiple metastases usually receive whole brain irradiation
(WBI) [5]. Patients with limited CNS metastases and
widespread systemic disease can achieve prolonged survival
with targeted treatment of CNS lesions and aggressive
systemic therapy—chemotherapy.
Gamma Knife radiosurgery or surgical resection of CNS
disease prior to chemotherapy improves survival versus
delayed treatment in patients melanoma with melanoma
brain metastases [4]. Radiotherapy is recommended to
t h o s ec a s e sw h e r et o t a lr e s e c t i o nw e r en o tp o s s i b l ea n dt h e
concomitant use of corticoid pulse therapy is recommended
inordertoreduceperitumoral edemaandmass tumoreﬀect.
6.2.1. Surgical Resection. Surgery of an isolated metastasis
can lead to a long survival but brain lesions are frequently
numerous and associated with an extracerebral diﬀusion
(Figure 3). Complete surgical resection of intracranial
melanoma metastatic lesions results in a mean survival
period of 10.3 months. Patients with primary lesions of the
head and neck have lowest mean survival, about 3.3 months,
whereas those whose primary sites are unknown have the
longestmean survival, approximately7.5months. General 1-
and 2-year survival rates are 9% and 3%, respectively [29].
6.2.2. Whole Brain Irradiation (WBI). Duration and quality
of survival depend on the extent of metastatic disease and
response to treatment. Treatment goals with WBI are palli-
ation of symptoms and prolongation of life. Although brain
metastases may be treated with surgery and/or stereotactic
radiosurgery (SRS) when disease is limited to three lesions,
treatment for patients with large or multiple metastases is
limited to WBI.ISRN Surgery 5
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Figure 3: Sequence of surgical photos showingintraparietal exposition of a CNS metastatical melanoma lesion and its surgical excision.
While formal response and survival analyses of the
impact of WBI in melanoma metastases have not been
reported, the estimated mean survival time for unselected
patients with CNS metastases is only 2 to 4 months, with 1-
yearsurvival rates oflessthan 13%.This rates preventtheuse
of WBI as single therapeutic option. In a selected population
of patients with limited CNS involvement, surgical resection
alone or in combination with WBI appears to prolong
mean survival. Overall survival is signiﬁcantly improved
in patients with multiple metastasis who receive adjunctive
cranial irradiation versus those who had surgery alone [30].
Therefore, adjunctive cranial irradiation is justiﬁed for
melanomapatientswhoundergosurgicaltherapyforsolitary
brainmetastases. Survivalinpatientspresentingwithsolitary
brain metastases is improved by a reduction of relapse in the
brain as a component of failure by combined surgery and
irradiation. In these patients survival will depend basically
upon control of systemic disease Some authors even suggest
the prophylactic whole brain irradiation for patients with
melanoma that present high risk of metastases, once CNS
metastases are sometimes the sole site of clinical relapse, and
are frequently disabling [31].
6.2.3. Accelerated Irradiation Regimens. In accelerated irra-
diation regimens, the total tumor dose varies from 3000 to
4800rad, and the overall treatment time from 1 to 2 weeks.
This more aggressive form of treatment has demonstrated
no signiﬁcant improvement in the results from accelerated
fractionation in the treatment of intracranial metastases.
The result of the radiotherapy treatment did not depend
on the site of the primary lesion, number of intracranial
metastases, total dose, or the dose perfraction. There are,
however, two subgroups not mutually exclusive, that beneﬁt
signiﬁcantly from the acceleratedfractionation: patients who
had a complete resection of brain metastases, and those
having no detectable extracranial metastases at the time of
their treatment for intracranial metastases [19].
6.2.4. Chemotherapy. Although in larger metastases the
blood-brain barrier is leaky, lesions are resistant to
many chemotherapeutic drugs. While systemic therapy for
metastatic melanoma produces objective responses in 15%
to 50% of patients, available drugs do not penetrate well
into the CNS, and these patients rarely beneﬁt from systemic
therapy [6].
(a)Dacarbazine. Dacarbazine(DTIC)givesameanresponse
rate of 21% on visceral localizations but does not cross the
blood brain barrier (BBB). Biological response modiﬁers
like Interleukin 2 (Il2) leads to a 25% response rate in
disseminated melanoma [29].
(b) PCNU. The results indicate that systemic PCNU is
unlikely to be more eﬀective than other currently used
chemotherapy in patients with malignant melanoma and
CNS metastases [32]. Moreover, treatment with PCNU
presents frequently some acute complications like granulo-
cytopenia or thrombocytopenia.
(c) Temozolomide. Temozolomide (TMZ) is a novel oral
alkylatingsimilartodacarbazine(themostactivesingleagent
in primary melanoma) that have 100% oral bioavailability
and considerable penetration of CNS tissue. TMZ has
broad preclinical antitumoral activity that in melanoma
is comparable to that of dacarbazine.Sites of remission of
metastatic melanomas treated with temozolomide include
brain, lung, liver, lymph nodes and muscle. Patients tolerate
treatment with termozolomide well and usually no dose
reduction is necessary. However some few patients may
present complications due to severe leucopoenia and throm-
bocytopenia (WHO grade 3 and 4). Thus, termozolomide
represents asafe treatment optioninpatientswith metastatic
melanoma and poor prognosis [33].
(d) Temozolomide Combinations. Temozolomide (TMZ)
may also be used in combination with interferon alpha-2b
(IFN-alpha2b).The most commonadverse eventsduringthe
use of this association are fatigue, fever, nausea/emesis, anxi-
ety, and diarrhea. Most toxicity is mild to moderate in sever-
ity. The primary dose-limiting toxicity is thrombocytopenia.
The maximum tolerated dose is either TMZ 150mg/m(2)
plus IFN-alpha2b 7.5MIU/m(2) or TMZ 200mg/m(2) plus
IFN-alpha2b 5.0MIU/m(2). The pharmacokinetics of TMZ
is not aﬀected by coadministration of IFN-alpha2b [33, 34].
ThecombinationofTMZandwholebrainirradiation (WBI)
was studied in patients with CNS metastatic malignant
melanoma, and it was found that, although TMZ can
be safely administered with WBI, the combination has
limited antitumor activity [35]. Another option for the
chemotherapy in patients with metastatic melanoma is the
use of termozolomide (TMZ) p.o. followed by subcutaneous6 ISRN Surgery
Table 1: List of available diagnostic methods, their speciﬁc utility and Results which suggeest CNS melanoma metastasis.
Diagnostic methods Suggestive result Speciﬁc utility
Computed tomography Hyperdense lesion Primary exam
Magnectic resonance Images Hyperintense lesion on T1 and hypointense
lesion on T2-weighted images More detailed exam
Optical coherence tomography Increased optical backscatter Intraoperatory exam
Positron emissiontomography High captation of compound
18F-10B-LBPA Noninvasive radiation dose planning
Cintilography Increased uptake of iofetamine High sensible method
Immunohistochemistry Finding of intermediate ﬁlament keratin Diﬀerentiating between metastatic melanomas
and primary central nervous system tumors
Monoclonal antibody Raise of ﬁbronectin, beta 2-microglobulin Diagnosis of metastatic meningeal
melanomatosis
Immunocytology IgM and IgG index, IL-6 and TNF-alpha Diagnosis of metastatic meningeal
melanomatosis
Transcriptase-polymerase chain reaction
(PCR)
Detection of melanoma-associatedmarkers
(MAGE-3, MART-1, and tyrosinase) Diagnosis of subclinical CNS metastases
Table 2: List of therapeutic options mean survival and speciﬁc indications of each method.
Treatment modality Mean Survival Indications
Surgical resection 10,3 months Limited (up to three) CNS metastases and widespread systemic
disease
W h o l eb r a i ni r r a d i a t i o n 2 – 4m o n t h s L a r g eo rm u l t i p l em e t a s t a s e s
Chemotherapy 8,3 months Widespread systemic disease and multiple CNS metastasis
Stereotactic Radiosurgery 1 year Small and solitary lesions
Gamma knife surgery 10,4 months Smalland solitary lesions
Boron neutron capture therapy Still in animal research phase —
(s.c.) low-dose interleukin-2 (IL2), granulocyte-monocyte
colony stimulating factor (GM-CSF), and interferon-alpha
2b (IFN alpha). The overall objective response rate Is
31%. Responses occur in all disease sites including the
central nervous system (CNS) [36]. The main toxicity of
this combined chemotherapy is the ﬂu-like syndrome and
transient liver function disturbances. The mean overall
survival with temozolomide reported is 7 months since
beginning of therapy.
(e) Fotemustine (Muphoran). Fotemustine (muphoran), a
new amino acid-linked nitrosourea, can give a response
rate up to 28.2% in patients with cerebral metastases, and
the increased survival of responding patients is signiﬁcant
[6, 29]. All responders to fotemustine have mainly cortical,
groupA(lesionsmallerthan1cm),orgroupBlesions(lesion
s between 1.1 and 4cm). Patients with group C metastasis
(lesion bigger than 4cm) or leptomeningeal spread do not
respond to fotemustine.
(f)Intracarotid Cisplatin. Intracarotid cisplatin-based chem-
otherapy may be useful for palliation in selected patients
with malignant melanoma and CNS metastases. Intrac-
arotid cisplatin 40–75mg/m2 can be administered alone,
with 1,3-bis(2-Chloroethyl)-1-nitrosourea (BCNU) or with
bleomycin. Thirty percent of the patients have objective
improvement in CT scans and about 13% of them have sta-
bilization of disease. The median time to tumor progression
for responding patients is 20 weeks. Neurological and retinal
toxicity are potential complications of this therapy [37].
(g) Interferon. Interferon apparently is inactive against mel-
anomabrainmetastases,butdoescauseCNSsymptoms[38].
6.2.5. Stereotactic Radiosurgery. More recently, stereotactic
radiosurgery (SRS) has been used as an eﬀective local
treatment for patients with CNS melanoma metastases. In
several retrospective reports, treatment with SRS alone or
in combination with whole brain irradiation (WBI) has
demonstrated to prolong mean survival [39]. As happens
with the treatment with WBI alone, most of the patients die
from progressive extracranial disease with locally controlled
CNS disease [6, 40].
6.2.6. Gamma Knife Surgery. Gamma knife surgery (GKS)
is eﬀective in treating melanoma metastases in the brain.
It appears that the radiobiology of a single high dose
overcomes the radioresistance barrier, yielding better results
than fractionated radiation. Twenty-four percent of the
lesions treated with GKS disappear, 35% shrink, 23% remain
unchanged, and 18% increasing size. No undue radiation-
induced changes are observed in the surrounding brain.ISRN Surgery 7
No deaths or neurological morbidity related to GKS is
observed. The mean survival time calculated is 10.4 months
from the time of treatment with GKS. Solitary brain lesions
and lack of visceral metastases are statistically predictive of a
better prognosis [12].
6.2.7. Boron Neutron Capture Therapy (BNCT). Boron neu-
tron capture therapy (BNCT) is yet an incipient therapy
method that has shown good results in rats experiments,
mainly if combined by either Cereport (RMP-7) medi-
ated modulation of blood-brain barrier (BBB) permeability
or hyperosmotic mannitol-induced BBB disruption using
borono-phenylalanine (BPA) as the capture agent. Optimiz-
ing the delivery of BPA by means of intracarotid injection
combined with opening the BBB by infusing Cereport or
a hyperosmotic solution of mannitol signiﬁcantly enhance
survival times and produce long-term cures in animals with
CNS melanoma metastasis. These observations are relevant
to future clinical studies using BNCT for the treatment of
intracerebral melanoma [41].
6.2.8.Prognosis. Prognosisforpatientswithmelanomabrain
metastasis is still poor with a mean survival time of 6 months
after diagnosis [1, 2, 5, 42]. Mean survival in patients treated
with chemotherapy is approximately 8.3 months—1 year
survival of 41%. Surgical resection allows mean survival
rates of 10,3 months. Estimated mean survival time for
patients with CNS melanoma metastases treated with whole
brain irradiation is only 2 to 4 months. Mean survival time
for patients treated with Gamma knife radiosurgery is 10.4
months [36].
7.Conclusions
Most of the symptoms of CNS melanoma metastasis are
unspeciﬁc and depend on localization of the lesion. CT
scan is recommended as the primary exam in case of
suspected cases. MRI must be used to study more precisely
the characteristics of the lesions in order to embase the
surgical plane. It is important that the clinician suspect of
the possibility of CNS metastasis in all patients with new
neurological signs and previous primary melanoma lesion.
These patients deserve a careful clinical analysis and further
exams for investigation (Table 1).
Optimal treatment of melanoma patients with CNS
metastases dependson the objectivesituation. Oftensurgery,
radiosurgery, whole brain radiotherapy and chemotherapy
are used in combination to obtain longer remissions and
optimal symptom relieve (Table 2). Patients with multiple
metastases usually receive whole brain irradiation (WBI).
Patients with limited CNS metastases and widespread sys-
temic disease can achieve prolonged survival with targeted
treatment ofCNSlesionsandaggressivesystemic chemother-
apy, when clinical conditions of patient allow. Stereotactic
radiosurgery is recommended to those cases where total
resection are not possible and, in this case, the concomitant
use of corticoid pulse therapy may be useful in order to
reduce peritumoral edema and mass tumor eﬀect. We highly
recommend “New Brain Metastases Treatment Guidelines”
issuedbytheAmericanAssociationofNeurologicalSurgeons
& the Congress of Neurological Surgeons published in the
Journal of Neuro-Oncology in 2009. It deals with speciﬁc
issues regarding the level of evidence of chemotherapy,
radiosurgery, surgical resection, whole brain radiotherapy,
use of corticosteroids, and anticonvulsants in the treatment
of brain metastases.
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